Atossa Therapeutics, Inc.

Stage 1 · Basing · week 14→1 today

As of Oct 22, 2026, Atossa Therapeutics is in Stage 1, the basing phase, now in its first week (since Oct 22, 2026). It closed at $2.72, 80.7% below its 52-week high and below its 200-day average, which is falling.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. More about the company

$2.72

+7.51% today

$27.1M · Micro cap

Market Neutral — Fading

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is ATOS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 16w

S4 23w

S4 19w

S4 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 2w → S3 5w → S4 11w → S1 7w → S2 16w → S3 12w → S2 12w → S3 2w → S4 23w → S1 12w → S4 9w → S2 8w → S3 3w → S4 19w → S1 5w → S4 14w → S1 2w → S4 2w → S1 1w current

Total tracked: 164 weeks across 19 stage runs.

ATOS among Biotechnology465th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…465	ATOSAtossa Therapeutics, Inc.	Stage 1 · wk 1	11	+24.8%

vs 52W High

-80.7%

$1.75 lo$14.10 hi

80.7% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 1

1w13w26w

Week 1, early base

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-34.7%

200 DMA: $4.17 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

1.18x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↑ ⇈

Short-term trend rising strongly, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+24.8%

+18.3%

-52.5%

YTD

-71.2%

-81.1%

Scan Membership

Breakout Watch

Latest: 2024-09-03

7 appearances in last 60 days. First seen: 2019-03-22.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S14→1

Wk 1 · Vol 1.18x

2026-10-21S4

Wk 3 · Vol 2.55x

2026-10-20S4

Wk 3 · Vol 0.49x

2026-10-19S4

Wk 3 · Vol 1.08x

2026-10-16S4

Wk 2 · Vol 1.43x

2026-10-15S4

Wk 2 · Vol 3.27x

2026-10-14S4

Wk 2 · Vol 3.60x

2026-10-13S4

Wk 2 · Vol 1.09x

2026-10-12S4

Wk 2 · Vol 1.26x

2026-10-09S4

Wk 1 · Vol 4.43x

2026-10-08S4

Wk 1 · Vol 1.72x

2026-10-07S4

Wk 1 · Vol 0.32x

Moving averages & range

50 DMA

$2.45

200 DMA

$4.17

52W High

$14.10

52W Low

$1.75

5D Low

$2.53

Resistance levels (recent highs)

20d High

$2.91

60d High

$2.91

120d High

$5.86

250d High

$14.10

Next resistance

+7.0%

to 20d High

ROE

-89.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.0

Atossa Therapeutics: quick answers

What stage is Atossa Therapeutics in?

As of Oct 22, 2026, Atossa Therapeutics (ATOS) is in Stage 1, the basing phase. It entered Stage 1 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Atossa Therapeutics in an uptrend?

Not yet. Atossa Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 34.7% below its 200-day average, which is falling.

How far is Atossa Therapeutics from its 52-week high?

Atossa Therapeutics closed at $2.72 on Oct 22, 2026, 80.7% below its 52-week high of $14.10. Its 52-week low is $1.75.

How has Atossa Therapeutics performed over the past year?

As of Oct 22, 2026, Atossa Therapeutics is down 81.1% over the past year and down 71.2% so far in 2026.

Which sector and industry is Atossa Therapeutics in?

Atossa Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.